Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immutol
- Development stage
- Preclinical
- Lead developer
- Fondazione Telethon
- Modality
- Cell Therapies, Gene Therapies
01
Overview
Immutol (also known as DCIL-10/Ag) is an investigational, second-generation tolerogenic cell and gene therapy designed to restore antigen-specific immune tolerance in patients with autoimmune diseases, primarily multiple sclerosis (MS). Developed under the EU-funded Horizon Europe IMMUTOL project, the therapy consists of autologous dendritic cells (DCs) differentiated in the presence of vitamin D3 (VitD3) and genetically engineered using a lentiviral vector to overexpress interleukin-10 (IL-10) and disease-specific immunodominant myelin antigens. This dual modification promotes the induction of antigen-specific regulatory T (Tr1) cells, which suppress pathogenic autoimmune responses without causing generalized immunosuppression. The program is currently in preclinical development, with efforts focused on optimizing GMP manufacturing and establishing clinical roadmaps for first-in-human trials.
- Other names
- DCIL-10/AgVitD3-DC-IL-10VitD-3-DC-IL-10VitD 3-DC-IL-10VitD3-DC-IL-10/AgVitD3DCIL-10VitD-3DCIL-10VitD 3DCIL-10
Beyond the preview
Go deeper on Immutol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immutol.